Articles from Immunis, Inc.

Immunis, Inc., a clinical-stage biotech developing multi-active biologics for age and disease-related immune dysregulation, has closed a $25 million Series A-1 financing round to fund two Phase 2 clinical trials. Follow-on investments from all major existing investors, notably, Remiges Ventures, Continuum Health Ventures and BOLD Capital Partners were joined by new investments from LifeSpan Vision Ventures and JLS Fund among others, including a leading global insurance company.

Immunis, Inc., a clinical-stage biotech developing novel secretome therapeutics for age-related diseases and immune dysfunction, was recently granted permission by the FDA to proceed with its Phase II clinical trial testing its investigational secretome (IMMUNA) in reversing sarcopenic obesity. The news comes shortly after Immunis completed secretome-treatment of its third patient cohort in a Phase I/IIa clinical trial for age-related muscle atrophy (sarcopenia).

Immunis, Inc., a clinical-stage biotech developing novel secretomes for age-related diseases and immune dysfunction, has initiated non-terminal safety studies with VetBio Partners, LLC for canine muscle atrophy. With the preclinical success of Immunis’ investigational secretome (IMM01-STEM, previously IMMUNA) in aged mouse models and the rapidly advancing clinical testing in its STEM-MYO and STEM-META programs, Immunis is pursuing a parallel STEM-K9 program in dogs.

Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and disease-related immune dysfunction, announced today its partnership with Springbok Analytics, a life sciences muscle analytics company. Springbok is building a new standard in muscle health with its MRI-based AI muscle analysis technology that is used widely throughout elite sports, human performance and life sciences. Immunis is using Springbok’s technology to evaluate the efficacy of its investigational secretome therapeutic, IMMUNA, in restoring muscle growth and function in a sarcopenic Phase 1/2a clinical trial population.

Immunis, Inc., a private biotechnology company developing regenerative secretomes for age and disease-related immune dysfunction, is delighted to welcome Dr. Christina Weng as its newest Advisory Board member. Dr. Weng is an accomplished physician-scientist, entrepreneur, and biotech executive. She is a board-certified dermatologist at the Massachusetts General Hospital and faculty at Harvard Medical School. An expert in regenerative medicine, she currently serves as the Chief Medical Officer of Pelage Pharmaceuticals, which targets stem cell metabolism to address hair loss.

Immunis, Inc., a clinical-stage biotech developing innovative secretome therapies to address age-related disease and immune dysfunction, obtained a significant strategic milestone in partnering with Toray, a Japanese drug company part of the Toray Group. Founded in 1926, Toray has grown into a highly successful conglomerate known for its commitment to solving pressing global health and environmental challenges. With its production of various advanced material sciences, Toray has diversified expertise in industries including pharmaceuticals, electronics, textiles, and aerospace.

Immunis, Inc., a private biotech company developing an innovative secretome for age-related diseases and immune dysfunction, announces that its Chairman, Dr. Hans Keirstead, will present at the annual Abundance360 in Los Angeles. Dr. Peter Diamandis is the world-renown entrepreneur and mastermind behind Abundance360, which fosters collaboration between prominent figures in space, technology, education, venture capital and longevity research.

Immunis, Inc., a private biotech company revolutionizing cellular secretome therapeutics, is proud to announce that its Chairman, Dr. Hans Keirstead, will present at the exclusive 13D Brain Trust Conference in the Bahamas. Brain Trust is a highly exclusive, invite-only event covering artificial intelligence, global technological advancements, innovative biotechnology, and unique investment opportunities. Like its name, the Brain Trust Conference invites the world’s greatest minds to realize their visions for the world.

Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, presents a one-of-a-kind film (The Time is Now) with world-renowned longevity innovators who examine the future of aging and human healthspan. Immunis was honored to host esteemed interviewees Dr. Peter Diamandis, Dr. Hans Keirstead, Dr. Daniel Kraft, and Jane Metcalfe, who all share the common goal of revolutionizing human health.

Immunis, Inc., a private biotech and a pioneering force in cellular secretome therapeutics, is thrilled to announce that its Chairman, Dr. Hans Keirstead, is an invited speaker at the exclusive Longevity Investors Lunch in Davos, Switzerland (hosted by Longevity Investors Conference). This prestigious event is celebrated for its role in uniting distinguished figures in biotechnology, investment, and research to delve into the most recent advancements and trends in the longevity sector. The conference will emphasize the importance of innovative therapeutic approaches in aging and longevity, showcasing cutting-edge developments in cellular therapies, genomics, and age-related disease management.

Immunis, Inc., a private biotech transforming the field of cellular secretome therapeutics, is excited to reveal that its esteemed Chairman, Dr. Hans Keirstead, will be a featured speaker at the upcoming 2024 Biotech Showcase in San Francisco. The Biotech Showcase is a distinguished event, renowned for bringing together global leaders in biotechnology, pharmaceuticals, and finance to explore the industry’s latest trends and innovations. This year's conference focuses on drug development in areas including oncology, cell and gene therapy, and rare diseases.

Immunis, Inc., a leading private biotech at the forefront of innovative immunomodulatory secretome therapeutics for age-related diseases, is proud to announce that its Chairman, Hans Keirstead, Ph.D., has once again been named one of Orange County Business Journal’s OC 500 for 2023. Selection for this honor is based on a comprehensive merit assessment, recognizing top executives, government leaders, philanthropists, and other prominent civic figures who have made significant contributions to the Orange County business community.

Immunis, Inc., a private biotechnology company developing innovative secretome therapeutics for age and disease-related immune dysfunction, is honored to win two 2023 Best of America Small Business Awards (BASA). Not only was Immunis recognized as the “Best Small Business” in biotechnology, but Immunis’ Chairman, Dr. Hans Keirstead, was also awarded “Best Entrepreneur.” These accolades are a testament to the company's innovation, excellence, and leadership in the competitive and rapidly evolving field of biotechnology.

Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, proudly announces that its Chairman, Dr. Hans Keirstead, will present at BIO Europe in Germany. With over 5,000 attendees, the conference gathers key stakeholders and thought leaders in the biotechnology space, serving as an exceptional platform for sharing breakthroughs, fostering collaborations, and charting the future of biomedicine.

Immunis, Inc., a private biotech revolutionizing cellular secretome therapies to address age and disease-related immune decline, is thrilled to announce its selection as a finalist for the Best of America Small Business Awards (BASA). The BASA awards celebrate the resilience, creativity, and indispensable role that small businesses play in enhancing economic growth and social responsibility.

Immunis, Inc., a leading biotechnology company forging innovative cellular secretome therapies for age and disease-related immune decline, is delighted to announce that its Chief Business Officer, Mark Cabato, will be a keynote speaker at this year's Drug Discovery Strategic Summit.

Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, is pleased to announce that its Chairman, Dr. Hans Keirstead, will be taking center stage at the prestigious Innovative Therapies Days conference in Besançon, France. Innovative Therapies Days is a premier event in medical innovation, showcasing presentations from esteemed clinicians, scientists, and industry partners. This year, the conference will focus on cutting-edge technologies using stem cells, cellular secretomes, CAR-T cells, and much more.

Immunis, Inc., a private biotech company creating novel cellular secretome therapies for age and disease-related immune decline, is delighted to have Professor Irina Conboy on its Scientific Advisory Board. Dr. Conboy is a Professor of Bioengineering at UC Berkeley, investigator at the Quantitative Biology Institute, and Editor in Chief of Rejuvenation Research. Her groundbreaking studies have unveiled critical paradigms on the effects of age-related and pathological changes on tissue maintenance and repair, setting the stage for novel therapeutic interventions.

Immunis, Inc., a private biotech developing innovative cellular secretome therapies for age and disease-related immune decline, is thrilled to announce that its Chairman, Dr. Hans Keirstead, will be taking center stage at the prestigious Festival of Biologics in Basel, Switzerland. The Festival of Biologics is a pivotal meeting for the life science community, encompassing the entire spectrum of biologics, from drug discovery and development to manufacturing, clinical trials, and commercialization. Dr. Keirstead's presence supports Immunis' position at the forefront of biotechnological research and dedication to enhancing global health through innovation.

Immunis, Inc., a private biotech company developing novel cellular secretome therapies for age and disease-related immune decline, is delighted that its Chairman, Dr. Hans Keirstead, will present at the Advanced Therapies Conference in Portugal. The Advanced Therapies Conference is a premier gathering of thought leaders and pioneers from around the globe, engaging in discourse on the latest innovations in therapeutic research.

Immunis, Inc., a private biotech and a leading innovator in cellular secretome therapies for age and disease-related immune decline, is honored to be selected as a finalist for the "Best Emerging Technology Company" by the Octane High Tech Awards (HTA). The HTA awards recognize exceptional technology companies that have made significant contributions to their respective industries through innovation, leadership, and outstanding achievements.

Immunis, Inc., a private biotech company developing a novel cellular secretome therapy for age and disease-related immune decline, is thrilled to announce that it has received unanimous approval from the Data Safety and Monitoring Board (DSMB) to proceed enrolling the next cohort of patients for its Phase 1/2a clinical trial.

Immunis, Inc., a private biotech company pioneering a novel secretome-based therapy for age and disease-related immune decline, is thrilled to announce its nomination for the prestigious Prix Galien Award for "Best Startup."

Immunis, Inc., a private biotech company developing a novel secretome therapeutic for age and disease-related immune decline, releases an informative article about the incredible potential of secretomes. The article entitled “The (Secret)ome to Longevity” was written by Immunis’ Senior Scientific Communications Manager, Karissa Munoz, Ph.D.

Immunis, Inc., a private biotech company developing an innovative secretome therapeutic for age and disease-related immune decline, shares a video featuring the leading edge-capabilities of its infrastructure. Immunis invites everyone to learn about the significant coordination efforts of turning the vision of IMMUNA into a potentially life-changing treatment.

Immunis, Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, has appointed Neil Sahota as its Chief Artificial Intelligence (AI) Officer. AI is a tool that is transforming the way businesses and scientists integrate information, conduct data analysis, and make informed decisions on how to optimize growth. For over 20 years, Neil has inspired AI modernization through technology-based business strategies and has been successful in helping businesses become leaders in the digital future. Immunis is confident that Neil will guide the company to unlock the considerable potential of AI in biotech.

Immunis, Inc., a private biotech company developing an innovative treatment for age and disease-related immune decline, announces its first-in-human injection of IMM01-STEM for its STEM-MYO Phase 1/2a clinical trial. The goal is to assess the safety and tolerability of Immunis’ investigational stem cell secretome product, IMM01-STEM, in patients with muscle atrophy related to knee osteoarthritis, an inflammatory disease contributing to age-related disability. Immunis is actively recruiting patients for the trial in collaboration with the California Institute of Regenerative Medicine (CIRM) Alpha Clinic.

Immunis, Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, announces that its Chairman, renowned neuroscientist Hans Keirstead, Ph.D., visited the Dalai Lama again this past week in His home in Dharamsala, India. The Dalai Lama remains a symbol of the unifying philosophy of Buddhism, where He is respected internationally as an educator of harmony and happiness for humanity.

Immunis, Inc., a private biotech company generating an innovative treatment for age and disease-related immune decline, announces that its Chairman, Dr. Hans Keirstead, delivered a keynote on behalf of the National Institute of Child Sexual Assault (NICSA) at the UN General Assembly in New York City. As part of Immunis’ ongoing Corporate Social Responsibility Program, Dr. Keirstead presented a keynote on child sexual assault (CSA), which aligns with the United Nation’s efforts to eradicate human trafficking and eliminate emotional, economical and physical violence against children and women.